Yu Zhang

Chinese Academy of Medical Sciences & Peking Union Medical College — China

Medicine · Health Sciences

21h-index1.2kcitations115works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(70), Hematopoietic Stem Cell Transplantation(29), Chronic Myeloid Leukemia Treatments(22), Acute Lymphoblastic Leukemia research(18), Histone Deacetylase Inhibitors Research(13)

Publications115 total

Methylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation
Ecotoxicology and Environmental Safety·2025· 1 citedOpen Access
The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China
Science China Life Sciences·2025
Single-cell profiling of long non-coding RNAs in the hematopoietic system
Blood Science·2025Open Access
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
British Journal of Haematology·2025· 2 cited
Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma
Frontiers in Immunology·2025· 1 citedOpen Access
SLC25A21 correlates with the prognosis of adult acute myeloid leukemia through inhibiting the growth of leukemia cells via downregulating CXCL8
Cell Death and Disease·2024· 2 citedOpen Access
Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine
Blood·2024Open Access
The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study
Blood·2024Open Access
Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis
Leukemia & lymphoma/Leukemia and lymphoma·2024· 5 cited
Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies
American Journal of Case Reports·2024· 1 citedOpen Access
Variable selection and subgroup analysis for high-dimensional censored data
Statistical Theory and Related Fields·2024· 5 citedOpen Access
Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis
PLoS Pathogens·2024· 11 citedOpen Access
Impact of measurable residual disease in combination with <scp>CD19</scp> on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission
Cancer Medicine·2024· 2 citedOpen Access
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study
Blood Cancer Journal·2023· 11 citedOpen Access
Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
Blood·2023· 2 cited
The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia
Blood·2023· 1 citedOpen Access
Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study
Blood·2023· 2 cited
Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study
Blood·2023· 1 citedOpen Access
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with <i>FLT3‐ITD</i>: A multicenter phase 2 study
Journal of Internal Medicine·2023· 22 cited
Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study
Annals of Hematology·2023· 3 cited
page 1 of 6Next →

Frequent Co-authors

Qifa Liu(19), Zhiping Fan(13), Fen Huang(12), Pengcheng Shi(10), Guopan Yu(10), Jing Sun(10), Na Xu(9), Sijian Yu(7), Min Dai(7), Li Xuan(7), Hui Liu(7), Zhiqiang Sun(6), Xinquan Liang(5), Ziwen Guo(5), Yu Wang(5), Jun Xu(5), Hua Jin(4), Xin Du(4), Ruoyang Shao(4), Dongjun Lin(4)